Increased risk for developing any dyslipidemia seen during 2020 to 2022
THURSDAY, Nov. 14, 2024 (HealthDay News) — There was an increase in dyslipidemia incidence during the COVID-19 pandemic compared with the prepandemic period, according to a study published online Sept. 12 in the Journal of Clinical Investigation.
Valentina Trimarco, from Federico II University in Naples, Italy, and colleagues conducted a six-year longitudinal study to examine the broader effects of COVID-19 on the incidence of dyslipidemia in a real-world population of 228,266 individuals. Dyslipidemia incidence was compared during the COVID-19 pandemic (2020 to 2022) to the prepandemic period (2017 to 2019), with follow-up of at least 1,095 days (21,349,215 person-years).
The researchers found that the risk for developing dyslipidemia was increased during the COVID-19 period compared with the pre-COVID-19 period (odds ratio, 1.29), after adjustment for comorbidities in a multivariate analysis.
“The main finding of our study is the observation that the increased risk of dyslipidemia during the COVID-19 pandemic involved not only patients who had severe acute respiratory syndrome coronavirus 2 infection but the whole population,” the authors write.
AI Better Assesses Heart Function From MRI Than Clinicians 
Maternal Night-Shift Work Tied to Later Neurodevelopmental Issues in Offspring 
Bariatric Surgery Is Effective Rescue Strategy After GLP-1 Receptor Agonist Failure 
Recommendations Provided for Managing Shift Work Disorder 
Past Blast Exposure Tied to Long-Term Chronic Medical Diagnoses in Veterans 
Sleep Disturbances, Duration Linked to Working Life Expectancy .jpeg)
Occupational Exposure to Pesticides Linked to Risk for ALS 
TBI Linked to Elevated Transition Probabilities to Work Disability 
